An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the 'Pamerit' study

Alessandra Mosca, Ugo De Giorgi, Giuseppe Procopio, Umberto Basso, Giacomo Cartenì, Melissa Bersanelli, Emanuele Naglieri, Luca Galli, Orazio Caffo, Giuseppe Fornarini, Francesco Boccardo, Camillo Porta

Research output: Contribution to journalArticlepeer-review

Abstract

OBJECTIVE: Despite the current immunotherapy era, VEGFR inhibitors maintain effectiveness in metastatic renal cell cancer. Real-world data concerning pazopanib are limited. The aim of this study is to add information about efficacy and safety of pazopanib as first-line treatment in metastatic renal cell cancer patients not enrolled into clinical trials.METHODS: Retrospective analysis (the PAMERIT study) of first-line pazopanib in real-world metastatic renal cell cancer patients among 39 Centers in Italy. Outcomes were progression-free survival, overall survival, objective response rate and treatment-related adverse events. Kaplan-Meier curves, log-rank test and multivariable Cox's models were used and adjusted for age, histology, previous renal surgery, International Metastatic RCC Database Consortium score and pazopanib initial dose.RESULTS: Among 474 patients, 87.3% had clear cell metastatic renal cell cancer histology. Most of them (84.6%) had upfront renal surgery. Median progression-free survival and overall survival were 15.8 and 34.4 months, respectively, significantly correlating with International Metastatic RCC Database Consortium's good prognosis (P <0.001), ECOG PS 0 (P <0.001), age (
Original languageEnglish
Article numberhyaa193
Pages (from-to)1-8
Number of pages8
JournalJapanese Journal of Clinical Oncology
DOIs
Publication statusPublished - Nov 20 2020

Fingerprint Dive into the research topics of 'An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the 'Pamerit' study'. Together they form a unique fingerprint.

Cite this